Response to Comments: MolDX: Prolaris Prostate Cancer Genomic Assay, L36340

The supplied document is a Noridian response to comments for the MolDX Prolaris assay (L36340) with a comment period ending 2015-03-30; the excerpt contains no explicit coverage indications, limitations, frequency limits, or claim documentation requirements. Manual review of the full policy text is required to extract actionable Medicare/Medicaid coverage criteria. Confidence in extraction is low due to missing policy content.

"Source document is a Noridian response to provider comments regarding the MolDX Prolaris Prostate Cancer Genomic Assay (L36340) for comment period ending 2015-03-30; no explicit coverage criteria a..."

Sign up to see full coverage criteria, indications, and limitations.